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Hypersecretion  of mucus  accompanies  pulmonary  diseases  such  as  asthma, 
bronchitis, and pneumonia, among others.  Neither the role  of mucus nor the 
mechanisms responsible  for  controlling its  secretion  in  these  diseases  is  clear 
although  recent  studies  have  uncovered  a  number  of putative  secretagogues 
including neurohormones (1-5), mast cell-derived mediators of allergy (4, 6-8), 
and  oxidative  derivatives  of arachidonic acid  (6-9)  able  to  stimulate  mucous 
glycoprotein release in vitro. 
The pulmonary macrophage (PM) 1 is the resident phagocytic cell in the lung 
and functions as the first line of defense against inhaled particulates. Because of 
the nature of its motility, phagocytic capability, and secretion of multiple prod- 
ucts,  the PM is thought to participate in lung inflammation both as a  primary 
cell in host defense and to recruit other cell types to the lung (10,  11).  It is likely 
that  PM  participate  in  some  manner  in  each  pulmonary  condition  in  which 
increased mucus secretion is associated, although no relationship between  PM 
and mucus secretion has previously been reported.  We undertook this study to 
investigate whether PM could elaborate factors able to stimulate mucus secretion 
and thus participate in this lung function as well. 
Materials and Methods 
Preparation of Human  Airways for  Culture.  Human  lungs were  obtained at  surgery 
primarily from tumor resection. All of the subjects from whom lung tissue was obtained 
were former or current smokers, and no attempt to correlate their pulmonary function 
with mucus secretion was made. Normal-appearing airways, 9-10 mm diam, were frag- 
mented into 3 ×  5-mm replicates and cultured as described (4, 6). The airway explants 
were maintained in CMRL-1066 medium (Gibco  Laboratories, Grand Island, NY) with 
penicillin (100 gg/ml), streptomycin (100 #g/ml), and amphotericin B (0.5  #g/ml) in a 
controlled atmosphere chamber gassed with 45%  O~, 50%  N~, and 5% CO~, and were 
incubated at 37°C. 
Radiolabeling of Mucous Glycoproteins.  Mucous glycoproteins were radiolabeled by in- 
corporating [~H]glucosamine  (1  uCi/ml) (New England Nuclear, Boston, MA) into the 
culture  medium.  Explants  were  initially incubated  for  16  h  in  the  absence  of [SH]- 
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glucosamine, washed twice with media, and then incubated with [3H]glucosamine for a 
16-h baseline period (period I). After period I supernatants were harvested, fresh culture 
media without [SH]glucosamine was added for an additional 4-h period (period II), and 
these supernatants were subsequently harvested. Glucosamine-labeled mucous glycopro- 
teins were precipitated from the samples by adding an equal volume of 95% ethanol. The 
precipitates were filtered through 0.45-~m membrane filters (Gelman Sciences, Inc., Ann 
Arbor, MI) and the retained radioactivity was determined. 
Effect of Pharmacologic  Manipulation upon the Release of Mucous Glycoproteins.  The effect 
of pharmacologic manipulations on the release of [3H]glucosamine-labeled mucous gly- 
coproteins was determined by adding agents to cultures at the beginning of period II. A 
ratio of the radiolabeled, precipitated counts per minute of period II to that of period I 
for each sample was determined and termed the secretory index.  Due to the relatively 
high secretory index observed in day  I  cultures, no experiments were done during the 
initial cycle. Instead, all experiments were performed on the lung specimens between days 
2 and 7 in culture. 
The  effects of pharmacologic agents  were  determined  by comparing the  secretory 
indices  of manipulated  samples with  matched,  unmanipulated  control  samples.  These 
samples were derived from the same tissue, cultured in parallel, and handled identically 
to the experimental samples except that pharmacologic agents were not added.  Thus, 
each airway culture  provided its own baseline period (period I) as well as a  stimulated 
period (period II), and the effects of each pharmacologic manipulation could be compared 
with matched controls. 
Macrophage Cultures.  PM were isolated from samples of human lung using a  modifi- 
cation of a  previously reported procedure (12).  Human lung specimens were placed in 
4°C sterile, heparinized saline immediately after surgical removal. The tissue was main- 
tained at 22 °C in Hanks' balanced salt solution (HBSS) 1 without Ca  2+ or Mg  2÷. Fragments 
(0.5 by 0.5 cm) of human lung parenchyma were teased apart, filtered through two layers 
of sterile surgical gauze, and centrifuged at 500 g for 10 rain at 22°C. Cell pellets were 
pooled,  layered  onto  Hypaque-Ficoll  (lymphocyte  separation  media;  Pharmacia  Fine 
Chemicals, Piscataway, N  J), and centrifuged at 1,000 g for 20 min at room temperature. 
The mononuclear cell preparations were removed from the interface, washed four times 
in HBSS, and resuspended in medium CMRL-1066 with penicillin (100 U/ml), strepto- 
mycin (100 #g/ml), and L-glutamine (100 mM) (Gibco Laboratories), without supplemen- 
tary serum. The concentration of PM was adjusted to 3-3.5 ×  106 cells/2 ml. Cells were 
allowed to adhere to plastic dishes for 4 h and then washed vigorously three times with 
serum-free media to remove nonadherent cells. The adherent cells were incubated for 24 
h  in  CMRL-1066  without  serum at  37°C  in  room air with  5%  CO2  in  a  humidified 
atmosphere before starting experiments. The percent viability of the cells was assessed by 
trypan blue exclusion after incubation in a  1% solution of the dye, and the viability always 
exceeded 96%.  Differential counts (Wright-Giemsa-stained cytocentrifuge preparation) 
revealed that the final cell preparations consisted of 95% macrophages and 5% lympho- 
cytes. The cells were removed from the culture plates with a rubber policeman, washed, 
and stained by the nonspecific esterase procedure of Burston (13);  96% of the cells were 
positive. The combination of morphoiogic appearance, staining characteristics, and phag- 
ocytic capabilities (to be described below) indicate that at least 95% of the cells were PM. 
No attempt to separate alveolar and interstitial macrophages was made. 
Zymosan Preparation.  Zymosan particles (Sigma Chemical Co.,  St.  Louis,  MO)  were 
suspended in sterile saline, boiled three times for 5 rain, and washed three times with 30 
vol of saline. The particles were then suspended 1:1 in normal human serum and incubated 
for 30 min at 37°C. The serum-treated zymosan particles were washed three times with 
30 vol of 0.5 M NaCI and finally resuspended in the incubation buffer before their use. 
Nonactivated zymosan was handled in an identical fashion except that these particles were 
not exposed to serum. Activated or nonactivated zymosan was added to the cells in culture 
at a ratio of 150 particles per PM. Supernatants were removed at different intervals (as 
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Millex-GV sterilizing filter units (Millipore  Corporation,  Bedford,  MA), and applied  to 
airways in culture (usually 2 ml/plate) at the beginning of period II. 
An alternative  experimental  design  was also used in which  PM  were incubated  with 
activated zymosan (10 mg/ml) for 60 min, the cultures were washed extensively to remove 
free zymosan, and the incubation subsequently continued for 8  h. The supernatant was 
then processed in a fashion identical to that described above. 
Manipulation  of Sera for  Zymosan  Activation.  Sera  used  for  zymosan activation  were 
obtained from healthy volunteers,  permitted  to clot  15-30 min at 4°C,  centrifuged at 
3,000 g at 4°C for 15 rain, and stored as aliquots at -70°C. An aliquoted serum sample 
was heat inactivated at 56°C for 30 min.  Rat sera were collected in a  fashion similar to 
that  described  for human sera.  Cobra venom factor (CVF)-treated  sera  were obtained 
from rats that had received CVF (250 U/kg; Cordis Laboratories, Miami, FL) in a single 
intravenous  bolus.  Blood was withdrawn  6  h  later  and  had  a  CHs0  level  of <1  U/ml 
(normal, 151 +  3.5 U/ml) and a C3 titer of <5.0 hemolytic U/ml (normal, 48,959 +  2844 
hemolytic U/ml) (14). Sera from a C3-deficient patient was kindly provided by Dr. Carl 
Hammer, National Institutes of Health. 
Preparation of Various Particles for Phagocytosis.  Sepharose 4B (Pharmacia Fine Chemi- 
cals) was washed three times with saline,  incubated with normal serum at a  1:1  dilution 
for 30  min at  37°C,  washed  three  more  times,  and added  to macrophages in culture. 
Latex beads (polystyrene, average diam 1.1 #m; Sigma Chemical Co.) were washed three 
times in saline before use.  Preparations of formalin-fixed protein A  containing Staphylo- 
coccus aureus (Bethesda Research Laboratories, Bethesda,  MD) were washed five times in 
saline, resuspended at a 2% concentration in saline, and added to cultured macrophages 
at  10 bacteria per macrophage. S.  aureus that were deficient in protein A  were handled 
in an identical fashion. 
Determination  if Macrophage-derived  Mucus Secretagogue (MMS) Is Preformed  or Newly Syn- 
thesized.  PM  were isolated and divided into two portions,  each of 30 ×  106 cells.  One 
portion of cells was frozen in culture media at -70°C immediately after isolation.  The 
other portion was cultured, incubated with activated zymosan or S. aureus for 1 h, washed, 
and cultured for eight additional hours.  After the supernatants  were collected, the cells 
were removed from the culture plates with a rubber policeman and were frozen at -70 °  C. 
Thereafter,  the cultured  PM and the cells that had been frozen directly after isolation 
were handled in parallel. The PM were freeze-thawed three times, sonicated in ice (3 min 
at  power  setting  3,  using a  microtip,  model  W185-F;  Heat  Systems-Ultrasonics,  Inc., 
Plainview, NY) and centrifuged at 3,000 g for 15 min at 4°C. The lysate was filtered in 
the cold through 0.22-#m  membranes and added to airways in culture to assess mucus 
secretagogue activity. 
Partially purified  MMS was obtained by ultramembrane  filtration,  gel filtration,  and 
isolectric focusing (see below). The MMS was then mixed with PM lysates for 4 h at 37°C, 
filtered on 0.22-#m membranes, and added to airways in culture. 
In a related experiment,  PM were cultured in the presence (or absence, in parallel) of 
cycloheximide  10 ~g/ml  (Sigma Chemical Co.) for  16 h.  These sets of cells were then 
exposed to activated zymosan or S. aureus for 1 h, after which the cultures were washed 
and  the  cells  cultured  for an  additional  8  h.  The  supernatant  was assayed  for  MMS 
activity. The cells were removed from the plates,  freeze-thawed,  sonicated as described 
above, and assayed for mucus secretagogue activity. 
To determine  if the cycloheximide affected macrophage protein synthesis,  its effects 
on leucine incorporation were studied.  Two sets of four culture plates each of PM were 
maintained in parallel to those used for MMS release; one was incubated with cyclohexi- 
mide, the other not. Both sets of cultures were exposed to S[H]-L-leucine (59.2 Ci/mmol; 
New England Nuclear Co.) for 1 h simultaneously with the addition of activated zymosan 
to the cultures. These PM were manipulated in parallel to replicates used for assessment 
of  MMS  activity.  After  the  incubations  were  completed,  the  cells  used  for  leucine 
incorporation were scraped from the plates and lysed by sonication; the  protein in the 
lysate was precipitated by the addition of an equal volume of 10%  perchloric acid. The 
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resuspended in water; the incorporated radioactivity was determined by liquid scintillation 
counting. 
Relationship Between Eicosinoids and MMS.  The PM were incubated with acetyisalicylic 
acid,  indomethacin  (Sigma Chemical  Co.),  or  eicosa-5,8,11,14-tetraynoic  acid  (ETYA) 
(kindly provided by Dr. W.  E.  Scott,  Hoffman LaRoche,  Inc., Nutley, N  J) for 60 min 
before the addition of activated or nonactivated zymosan. The zymosan-PM incubation 
was continued  for 60  min,  the  cells were  washed  three  times,  and  the  cultures  were 
maintained for eight more hours after which the supernatant was examined for mucus 
secretagogue activity. The agents above were prepared as described (6). 
Supernatants rich in mucus secretagogue activity were prepared by incubating PM with 
activated zymosan as described above. Such supernatants were adjusted to pH 3.0 with 
citric acid and extracted three times with 3 vol each of ethyl acetate or diethylether. The 
organic phase of each extraction was combined, evaporated to dryness under nitrogen, 
and resuspended in tissue culture medium before being assayed for mucus secretagogue 
activity. 
Supernatants rich in MMS activity were partially purified by ultramembrane and gel 
filtration (see below). These partially purified preparations were assayed by radioimmu- 
noassay for the presence of prostaglandin E (PGE), PGF2~, and thromboxane B~ (15). As 
used for this study, these assays were sensitive to 2.5 pg. 
Preparations of MMS were also fractionated on Amberlite XAD-7 (Mallinckrodt Inc., 
St. Louis, MO). A column of Amberlite (0.5 X 5 cm) was flushed alternatively with 20 vol 
of diethylether or water in preparation for the chromatography. Three different materials 
were fractionated and each was placed on the column in a volume of 20 tA. The materials 
were  [3H]leukotriene  (LT)  B4  (kindly  provided  by Dr.  Edward  Goetzl,  University  of 
California, San  Francisco,  CA),  1 #g of LTC4 (kindly provided by Dr.  Michael  Bach, 
Upjohn Co., Kalamazoo, MI), or MMS prepared by sequential fractionation using ultra- 
membrane filtration,  gel filtration, and isoelectric focusing (see below). After charging 
these materials onto the column, 5 vol of water followed by 5 voi of diethylether were 
added to the column. The MMS activity in the water fraction was assayed after lyophili- 
zation  and  resuspension  in  water;  the  ether  eluate  was  evaporated to  dryness  under 
nitrogen and resuspended in water before assay. 
Partial Purification of MMS.  50 ml of MMS-rich supernatant were obtained from PM 
incubated  with  activated  zymosan.  These  supernatants  were  pooled  and  sequentially 
filtered on  ultramembranes (YM10,  molecular weight exclusion  ~10,000,  and  UM05, 
molecular weight exclusion  ~500;  Amicon Corp.,  Danvers,  MA)  in  a  stirred chamber 
under nitrogen pressure (50 PSI) using water as the wash buffer. The UM05 retentate 
was concentrated to 1 ml, brought back to 50 ml with distilled water, and reconcentrated 
twice. The washed, concentrated UM05 retentate was lyophilized and resuspended in  1 
ml of culture medium. In these experiments, 20/~1 of the concentrate was added to the 
airways in culture to assess secretagogue activity. 50 ml of culture medium that had never 
been exposed to PM or which had been exposed to PM plus nonactivated zymosan were 
manipulated in parallel as controls. 
Concentrated UM05  retentate material was filtered on a  1 ×  60-cm Sephadex G-25 
column (Pharmacia Fine Chemicals) at 4°C, and fractions of 1.2 ml were collected. Each 
fraction was separately filtered through 0.22-#m membranes, lyophilized, resuspended in 
1 ml distilled water, and refiltered.  20 tzl of this material was then added to airways in 
culture. 
Concentrated  UM05  retentate  material  was analyzed by gel  filtration,  the fractions 
were assayed for secretagogue activity, and the active fractions were pooled (usually 2-4 
ml), lyophilized, and resuspended in 1 ml of water. One ml of fractionated MMS material 
was mixed with 58 ml Buffalyte solution (pH 3-10; Pierce Chemical Co., Rockford, IL) 
and 111 gm Pevikon (Accurate Chemical and Scientific Corp., Westbury, NY). The slurry 
was  poured  into  a  horizontal  isoelectric  focusing apparatus  (electrofocusing kit;  LKB 
Instruments, Inc., Gaithersburg, MD), and a pH gradient was established in 4 h using a 
constant power of 400  W  (LKB 2197  power supply) using the method of Harpel and 
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hydroxide, respectively. The slurry was divided into 5 fractions that were poured individ- 
ually into 1 x  6-cm columns and washed with 4 ml of water. The eluates were lyophilized, 
resuspended in 0.5 ml of water, and individually filtered over 1 x  60-cm Sephadex G-25 
columns as described above. 
Statistics.  The results are expressed as the percent increase in  mucous glycoprotein 
release  as  compared  with  control,  as  described  in  detail  (6).  Each  experiment  used 
quadruplicate airway cultures for determination of each point, and all results represent 
data observed from several experiments. The results are generally provided as the mean 
+ SEM. Statistical comparisons use paired sample t tests. 
Results 
Effect of Zymosan  on  the Release  of MMS.  To examine if PM  might influence 
mucus  secretion,  3  x  106  PM/plate  were  exposed  to  either  nonactivated  or 
activated zymosan particles (10 mg/ml). After 8 h of incubation, the supernatants 
were collected and added  to cultured  human airways that  were secreting [SH]- 
glucosamine-labeled mucous glycoproteins. As shown in Table I, the supernatants 
from macrophages cultured with nonactivated zymosan had no significant effect 
on airway mucus release (-0.6 _+ 3.0%, n =  8). By contrast, the supernatant from 
macrophages incubated with opsonized zymosan increased mucus release by 34.6 
+_ 7.8 % (n =  8, P  <  0.001).  Overall, 22 individual macrophage preparations have 
been exposed to activated zymosan as described and in every instance there has 
been  mucus  secretagogue  activity  in  the  supernatant.  The  effects  of  mucus 
secretion range  from  10  to 83%  above control.  Neither activated nor nonacti- 
vated zymosan had any effect when added to airway cultures directly. The factor 
in  the  supernatant  from PM  incubated  with activated zymosan will  henceforth 
be termed MMS. 
Dose  Response  of Zymosan  for  MMS  Release.  Macrophages  were  exposed  to 
0.01-100  mg/ml activated zymosan for 8 h, and the supernatants were added to 
the airways (Fig.  1).  In each of three experiments (pooled on Fig.  1),  concentra- 
tions  of  zymosan  >1  mg/ml  produced  near  maximal  release  of  MMS.  For 
TABLE  I 
Effects of Supernatants from PM Cultures on Human Airway Mucous 
Glycoprotein Release 
Mucus release (percent 
Source of supernatant  change from control) 
PM + activated zymosan  34.6 _+ 7.8 
n=8 
range,  12-83% 
PM + nonactivated zymosan  -0.6 _+ 3.O 
n--8 
range,-1 to 13 
P < 0.001 
PM were incubated with nonactivated zymosan or activated zymosan for 
8 h; the supernatants were pooled, centrifuged, filtered through 0.22-#m 
filters, and added to cultured airways. Results are the percent increase in 
mucous glycoprotein release as compared with control airways incubated 
in culture media alone. Zymosan at a concentration of 10 mg/ml was used 
in these experiments. Statistical comparisons are by paired sample t tests. MAROM,  SHELHAMER,  AND  KALINER  849 
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FIGURE  I.  Dose response of activated zymosan on MMS release. PM were incubated with 
0.01-100 mg/ml activated zymosan for 8 h. Supernatants were collected, pooled, centrifuged, 
filtered, and applied to human airways in culture.  The  results are the percent increase in 
mucus release as compared with control airways incubated in culture media alone. The results 
are the mean _  SEM of three separate experiments. 
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FIGURE 2.  Time  course  of the  appearance  of MMS.  PM  were  incubated with  activated 
zymosan (10 mg/ml) for  30  min to  16 h  before supernatants were removed and added  to 
airway cultures. 
convenience,  zymosan  was  used  at  10  mg/ml  (150  particles  per  PM)  in  all 
subsequent experiments. 
Time  Course of MMS  Release from  PM.  To  assess  the  time  course  of MMS 
release, PM were exposed to activated zymosan for from 30 min to 16 h before 
removal of the supernatant (Fig. 2). MMS was evident in cultures within 30 min 
of incubation and the release of MMS appeared to peak after 2-4 h. The time 
course of MMS  release  was repeated on  several other occasions and cultures 
exposed to zymosan for 24 h  appeared to have less activity than those at 4-16 
h.  Therefore,  4-to  8-h  incubations  with  activated zymosan were  considered 850  MACROPHAGE-DERIVED  MUCUS  SECRETAGOGUE 
optimal  for macrophages to release  MMS. The time course of MMS release in 
response to exposure to  10 or 20 mg/ml of activated zymosan were compared, 
and equivalent kinetics were observed. Therefore, within this narrow dose range, 
concentration did not seem to affect kinetics. 
Dose Response of MMS.  MMS  collected  from  PM  incubated  with  activated 
zymosan  for  8  h  was added  to  airway  cultures  in  dose  response  experiments 
(Table II). In two separate experiments, MMS, 0.5-2 ml, added to airways caused 
a  dose-related increase in  mucus release.  In  both experiments,  adding  1 ml of 
MMS-containing culture medium to  1 ml of ordinary culture medium resulted 
in significant increases in the release of mucous glycoproteins. 
Effect of Washing Macrophages on MMS Release.  Microscopic analysis  of PM 
exposed to activated zymosan indicated that  the zymosan was rapidly taken  up 
by the cells. We therefore examined whether a short initial exposure to activated 
zymosan followed by a longer incubation (to optimize MMS release) might be an 
acceptable design. In these experiments, PM were exposed to activated zymosan 
for either  8  h  (the  usual  experimental  design) or for  1 h  followed by washing 
and  an  additional  8-h  incubation.  The  supernatants  from  three  experiments 
using the two procedures were compared, and each generated equivalent degrees 
of increased mucus release (+31.1  _+ 1.3% for continuous zymosan exposure and 
+34  +  2.3%  for  1 h  of zymosan  exposure).  Therefore,  it  appeared  that  PM 
generate equivalent MMS either in the continuous presence of activated zymosan 
or after a  1-h exposure. 
Opsonization and Phagocytosis.  To analyze the requirements for zymosan acti- 
vation,  zymosan  was exposed to various sera before being incubated  with  PM 
(Table III). PM exposed to saline-treated zymosan generated no MMS. Zymosan 
that had been incubated in sera obtained from C3-deficient humans, CVF-treated 
rats, or after heat inactivation failed to stimulate macrophages to generate MMS. 
Only  zymosan  that  was  activated  in  normal  rat  or  human  sera  caused  the 
macrophages  to  release  MMS.  Thus,  complement  products  dependent  on  C3 
activation are required for zymosan to induce MMS release from PM. 
TABLE  II 
Dose Response of  MMS-containing Culture Media on Mucus Release 
Experi-  Supernatant  Mucus release (percent  p 
ment  added  increase above control) 
ml 
0.5  +1  +  1.3 (n =  5)  NS 
1  +18 _+ 2.0  <0.025 
1.5  +22 --- 4.0  <0.05 
2  +23 +  0.5  <0.0005 
B  1  +29 _  0.2 (n =  5)  <0.005 
2  +45 +  0.1  <0.0005 
PM were incubated with activated zymosan for 8  h  and the supernatants 
were  collected.  The  supernatants were  diluted  with  culture  media to a 
total final volume of 2  ml and added to cultured airways. Results are the 
percent increase over airways incubated in culture media alone. Statistical 
comparisons are by paired sample t tests. NS, not significant. MAROM,  SHELHAMER,  AND  KAL1NER 
TABLE  III 
Role of Complement in the Generation of  MMS 
PM plus: 
Mucus release 
(percent 
change from 
control) 
Zymosan incubated in normal human serum 
Zymosan incubated in heat-inactivated human serum 
Zymosan incubated in rat serum 
Zymosan incubated in CVF-treated  rat serum 
Zymosan incubated in C3-deficient human serum 
Nonactivated zymosan 
+23 ± 0.2 
+5 ±  1.3 
+32 ±  1.0 
+3 ± 2.0 
-5 ±  1.5 
0+0.4 
All zymosan and serum incubations were  done at 37°C for 30 min as 
described.  PM were incubated with these  zymosan particles (10 mg/ml) 
for 1 h. The supernatants were then removed and the cells were washed 
three times. Fresh medium was added and the cells were incubated for 8 
h, after which the supernatants were pooled,  centrifuged, filtered,  and 
added to human airways in culture. The results are the percent increase 
in mucus release as compared with control airways incubated in culture 
media alone. 
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TABLE  IV 
Capacity of Various Particles to Cause MMS Release 
Stimuli  Concentration 
Mucus 
release 
(percent 
increase 
above 
control) 
Activated zymosan  10 mg]ml  +28 ±  1.7 
Nonactivated  zymosan  10 mg]ml  +5 +  1.0 
Latex  0.05%  0 _  1.3 
Latex  1%  0 _+ 1.8 
Sepharose 4B and serum  0.05%  +26 ± 3.1 
Sepharose 4B without serum  0.05%  +8 ± 4.8 
S. aureus-protein A  10 bacteria/macrophage  +29 _+ 2.5 
S. aureus-nonprotein A  10 bacteria/macrophage  +7 ± 3.0 
PM cultures were exposed to the various particles for 60 min, after which the 
cells were washed and the incubation continued with fresh media (that did not 
contain phagocytic  particles) for 8 h.  The supernatants were  prepared as de- 
scribed for assessment of MMS activity. Each result is the mean _ SEM for three 
separate experiments. 
Phase microscopy of PM showed that phagocytosis occurred within 1 h  when 
zymosan particles opsonized in normal human or rat serum were used. Within a 
1-h period, there was little or no phagocytosis of zymosan particles that had been 
incubated with saline, C3-deficient human serum, heat-inactivated human serum, 
or  serum  from  rats  treated  with  CVF.  Thus,  phagocytosis  of  appropriately 
opsonized zymosan particles appeared to be associated with the release of MMS. 
To  address  whether  phagocytosis  itself  was  related  to  MMS  release,  the 
following experiments  were  performed  (Table  IV).  PM  were  incubated with 
Sepharose 4B that had been exposed to normal human  serum or buffer alone. 852  MACROPHAGE-DERIVED  MUCUS  SECRETAGOGUE 
The serum-treated  Sepharose 4B induced  MMS release from PM whereas the 
non-serum-treated  Sepharose did not.  As Sepharose is known to activate com- 
plement  (17)  but  is  too  large  for  ingestion,  this  observation  suggests that  at- 
tempted phagocytosis is sufficient for secretagogue release. However, incubation 
of PM with latex particles (either 0.05 or 1%) led to apparent active phagocytosis 
of the  particles,  as judged  by light  microscopy,  without  MMS  release.  Thus, 
phagocytosis by PM without concomitant opsonization is not an adequate stimulus 
for  MMS  release.  To  examine  if complement-derived  factors  were  the  only 
opsonins adequate  for MMS release,  the  effect of adding  S.  aureus  containing 
protein A on their surface was examined. A ratio of 10 bacteria per macrophage 
was used, and the staphylococci were observed to be actively ingested by the PM. 
In contrast to latex ingestion,  the phagocytosis of bacteria with protein A led to 
MMS release. However, incubation of PM with staphylococci that were deficient 
in protein A failed to generate MMS release. 
To  determine  if the  actual  act  of phagocytosis of activated  zymosan  was a 
prerequisite  for  PM  generation  of MMS,  the  effects of cytochalasin  B  were 
examined. Cytochalasin B disrupts microfilaments and inhibits phagocytosis (18, 
19).  The  PM  were exposed to cytochalasin  B  for  1 h  (either  5  or  15 gg/ml), 
incubated with activated zymosan for 1 h, and washed; the incubation was then 
continued for 8 h. The cultures were examined at 1 and 8 h by light microscopy; 
rosettes of zymosan  were observed on  the  surface  of the  PM  but no  obvious 
ingestion was apparent.  While the cytochalasin B impaired  the phagocytosis of 
zymosan by PM, there was no reduction in  MMS generation  by either  5 or  15 
gg. Thus, the supernatants  from zymosan-exposed PM increased mucus release 
by 22 _  2.3%,  and cytochalasin B-treated and  zymosan-exposed PM increased 
mucus release by 22 -+ 2.6%. Cytochalasin B in the absence of zymosan had no 
effect on PM viability or MMS generation. It appeared that cell-surface activation, 
but not actual phagocytosis, was sufficient to generate MMS release. 
Is MMS Preformed or Newly Synthesized?.  PM were exposed to activated zymosan 
or S.  aureus for 1 h and the cultures were washed and then incubated for 8 h to 
produce a supernatant  with MMS activity (Table V). After the collection of the 
supernatant,  the  PM  were removed from the culture plate and  lysed, and  the 
lysate was also assayed for MMS activity. The supernatants and lysates from PM 
that were exposed to nonactivated zymosan were also assessed for MMS activity 
as were lysates of purified PM that  had never been cultured in vitro. Only the 
supernatants  from  PM  exposed to  opsonized  zymosan  or  S.  aureus  contained 
MMS activity; none was observed in control cultures or in cultures exposed to 
nonactivated zymosan. PM lysates from all of these preparations failed to affect 
mucous glycoprotein release. 
Since it was possible that enzymes contained in the PM lysates might be able 
to degrade  MMS and  thereby falsely obscure MMS activity in the lysates,  PM 
lysates were also incubated with partially purified MMS. This partially purified 
MMS was obtained from supernatants  of cultured  PM after exposure to opso- 
nized zymosan; it was then sequentially filtered on ultramembranes and Sephadex 
G-25 and focused on a horizontal isoelectric focusing apparatus (see below). Such 
partly purified material increased mucous glycoprotein secretion from cultured 
airways by 17 _+ 6%. The partly purified MMS was incubated for 4 h with lysates MAROM,  SHELHAMER,  AND  KALINER 
TABLE  V 
Effects of PM Supernatants and Lysates on Mucous Glycoprotein Release 
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PM exposed to:  Preparation 
Mucus release 
percent 
change from 
control) 
Activated zymosan  Culture supernatant  +24 4- 2 
Lysate  -3 4- 8 
Culture media alone  Culture supernatant  0 4- 1 
Lysate  -3 4- 1 
Nonactivated zymosan  Culture supernatant  +4 4- 2 
Lysate  +3 +  1 
S. aureus  Culture supernatant  +32 4- 4 
Lysate  + 1 4- 3 
Lysate of PM not cultured in vitro  -9 4- 13 
Results from three separate  experiments,  each in quadruplicate,  are pooled and 
presented as the mean 4- SEM. 
TABLE  VI 
Effects of Cycloheximide on MMS Release from PM 
PM exposed to:  Preparation 
Mucus release 
percent 
change from 
control) 
S. aureus  Culture supernatant  +43 + 3 
Lysate  -9 + 3 
Cycloheximide  + S. aureus  Culture supernatant  -11 + 2 
Lysate  + 10 + 2 
Activated zymosan  Culture supernatant  +49 + 5 
Lysate  -2 4- 1 
Cycloheximide  + activated  Culture supernatant  -I-9 _  2 
zymosan  Lysate  + 12 4- 6 
Results from three separate experiments,  each done in quadruplicate,  are 
pooled and presented as mean 4- SEM. 
from PM, which had no effect on mucous glycoprotein release on their own (-2 
___ 3%).  Despite  the exposure  to PM  lysate,  the partially  purified  MMS  was still 
able to increase  mucus release  by  16 _  4%.  Thus,  MMS is not degraded by PM 
lysates,  and  the  inability  to detect  MMS  in  PM  lysates probably  means  MMS  is 
neither preformed  nor stored intracellularly. 
These data suggest that MMS activity might be newly synthesized after expo- 
sure  to  the  phagocytic  stimuli.  To  examine  this  possibility  further,  PM  were 
incubated  for  16  h  in  the  presence  or absence  of cycloheximide (20) and then 
exposed to either activated zymosan or S.  aureus,  and the capacity of these cells 
to generate  MMS activity was compared  with  non-cycloheximide-exposed  con- 
trois  (Table  VI).  PM  that  were  exposed  to  phagocytic  stimuli  released  MMS 
activity while  cycloheximide-exposed  PM  released  much  less.  While  these  data 
suggested  that  cycloheximide  interfered  with  MMS  synthesis,  cell  lysates  were 
also  examined  to  examine  if intracellular  MMS  was  generated  and  then  not 
released.  No intracellular  MMS was detected.  Protein synthesis by these cells was 854  MACROPHAGE-DERIVED MUCUS SECRETAGOGUE 
measured simultaneously to confirm one of the actions of cycioheximide (20). 
Control cells incorporated [~H]leucine into precipitable protein (1,208  _+  134 
cpm/106  cells),  while cycloheximide-treated cells incorporated only  106  +  30 
cpm. Thus, cycloheximide reduced leucine incorporation into precipitable pro- 
tein by 91%. These observations strongly suggest that MMS is newly synthesized 
through a cycloheximide-sensitive pathway. 
Do Eicosinoids Contribute  to MMS Activity?  PM were exposed to the cyclooxy- 
genase inhibitors, acetylsalicylic acid (100 #g/ml) or indomethacin (10 #g/ml), 
for  1 h  before the addition of activated zymosan and subsequent culture for 
MMS generation. In both instances, the cyclooxygenase inhibitors failed to affect 
MMS  release.  The  tissue  culture  medium  was  assayed  for  the  presence  of 
immunoreactive PGF2,~, PGE, and thromboxane B2 with assays sensitive to 2.5 
pg/ml  for  each.  The  tissue  culture  medium itself had  no detectable  PG  but 
stimulation of the PM with activated zymosan resulted in the generation of 99 + 
10 pg/ml PGF~,  170 +  18 pg/ml PGE, and 157 +  3 pg/ml TxB2. Preincubation 
of the PM with acetylsalicylic acid or indomethacin reduced immunoreactive PG 
generation below 10 pg/ml. Thus, two cyclooxygenase inhibitors failed to influ- 
ence MMS generation by PM but did prevent prostaglandin formation by these 
cells. These experiments were extended to examine the actions of ETYA (35 
~g/ml), which inhibits both cyclooxygenase and lipoxygenase pathways. ETYA 
preincubation also failed to influence MMS release by zymosan-activated PM. 
To  be  certain  that  eicosinoids  were  not  contributing  to  the  secretagogue 
activity, a  50-ml preparation  of MMS-rich culture supernatant  was generated 
from the culture of 75  ×  10  6  PM  and extracted, after acidification, into  the 
organic solvents, ethyl acetate or diethylether. Neither of the solvents, despite 
their capacity to extract PG,  monohydroxyeicosatetraenoic acids (HETE), and 
ieukotrienes, was able to remove MMS activity from the aqueous phase. Thus, 
MMS generation is not affected by inhibition of arachidonate metabolism nor 
extracted into the organic solvents commonly used in eicosinoid purification. 
The capacity of Amberlite XAD-7 to fractionate eicosinoids was also explored. 
Preparations of [~H]LTB4, LTC4, or MMS were added to Amberlite and eluted 
with water or ether (Table VII).  Both  LTB4 and  LTC4  fractionated into  the 
organic phase, as reflected by scintillation counting or increased mucus release, 
respectively. MMS activity eluted with the aqueous extract, reflecting its non- 
polarity  and  strengthening the  conclusions  that  MMS  does  not  derive  from 
arachidonic acid. 
Chromatographic Analyses  of MMS.  To obtain a rough estimate of the size of 
MMS, supernatants obtained from PM incubated with activated zymosan were 
filtered on ultramembranes. MMS was found to filter through a YM 10 membrane 
(indicating a size of <10,000 daltons) and to be retained by a UM05 membrane, 
suggesting that the size of MMS is between 500 and  10,000  D. Because of the 
ease of this procedure, ultramembrane filtration was subsequently used as the 
initial step in all purifications. Tissue culture media obtained from cultures of 
nonactivated PM failed to generate any MMS activity before or after fractiona- 
tion  on  ultramembranes.  Such  tissue culture media controls (devoid of MMS 
activity) were carried through all chromatographic analyses as negative controls. 
Over the course of these experiments, 10 separate preparations of MMS (after MAROM,  SHELHAMER,  AND  KALINER 
TABLE  VII 
Fractionation of  MMS on Amberlite XAD-7* 
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A. Fractionation of [~H]LTB4 
LTB4 added to column 
LTB4 in aqueous extract 
LTB4 in organic extract 
B. Fractionation of LTC4 
cpm/ml 
13,980 
1,800 
11,184 
Mucus release (percent 
increase above control) 
Starting activity  +56 _+ 3 
Aqueous extract  +14 +_ 4 
Organic extract  +42 _  3 
C.  Fractionation of MMS 
Starting activity  +35 +  1 
Aqueous extract  +28 ±  1 
Organic extract  + 10 +  1 
* LTB4, LTC4, or MMS were charged ohto 0.5 x  5-cm Amberlite XAD- 
7  that was  washed  with  5  vol  of water  (aqueous  extract)  and  5  vo] 
diethylether (organic extract). Results from single, representative exper- 
iments are  presented.  Results  in parts  B  and C  are  mean ±  SEM  of 
quadruplicates. 
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FIGURE 3.  Sephadex G-25 chromatography. 50-100 ml of supernatant obtained from PM 
incubated with activated zymosan were pooled and concentrated by ultramembrane filtration. 
The sample was then applied to a  1 x  60-ram Sephadex (;-25 column that was eluted with 
distilled water. The figure represents a summary of four chromatograms. Each fraction from 
the column was filtered, lyophilized, and resuspended in 0.5 ml of distilled water for assay of 
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uhramembrane fractionation) have been filtered through Sephadex G-25. Fig. 3 
presents the chromatographic pattern from the first four preparations,  which 
suggests that the major portion of MMS activity fractionated with an approximate 
molecular size of 2,000  D. The MMS activity of Sephadex G-25 fractions 24-26 
have  been  analyzed  in  six  subsequent  fractionations,  and  the  mean  (+_SEM) 
increase in mucus release by these fractions is 39.6  _+ 3.1%.  Material prepared 
by sequential ultramembrane and gel filtration  was examined to determine if 
MMS activity was dose dependent (Table VIIIA). 
Preparations of MMS were sequentially prepared by ultramembrane and gel 
filtration before horizontal isoelectric focusing on a Pevikon bed. Two separate 
preparations of MMS after isoelectric focusing are presented in Fig. 4.  In both 
instances, the major peak of activity focused at pH 5.15. A third preparation of 
MMS also focused at pH  5.15  (data not shown) indicating that this is a  highly 
reproducible  finding.  This  third  preparation  of partially  purified  MMS  was 
examined to determine if the MMS activity was dose dependent (Table VIIIB), 
which it was. 
Discussion 
Human PM release a  factor, MMS, which is able to cause human airways to 
release increased amount of biosynthetically radiolabeled mucous glycoproteins. 
This factor was released over a  4-8-h period after stimulation of the PM and 
was released by 22 of 22 human PM preparations examined. Zymosan was used 
as a convenient stimulus, but protein A-containing S.  aureus,  C3b-coated Sepha- 
rose beads, and concanavalin A (data not presented) are also effective stimuli. It 
initially appeared  that  phagocytosis was  a  prerequisite  for  MMS  release,  but 
several lines of evidence suggest that cell surface activation of macrophages is a 
TABLE  VIII 
Effects of Various  Doses of MMS on Mucus Release* 
A. MMS activity after ultramembrane and gel filtration 
Mucus release (percent increase above 
MMS added  control) 
1  15_+1 
10  28 -+ 2 
20  32 __. 2 
B. MMS activity after sequential uhramembrane filtration, gel filtration, 
isoelectric focusing, and gel filtration 
Mucus release (percent increase above 
MMS added  control) 
ul 
20  8_+7 
50  24 -4- 7 
75  62 +- 15 
* Results present the data from single representative dose response exper- 
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FIGURE 4.  Isoelectric focusing of MMS  on  Pevikon.  Two  preparations of MMS  (--  and 
---)  were filtered on ultramembranes and Sephadex G-25 and then applied to a  horizontal 
bed of Pevikon into which were incorporated ampholytes. The material was focused for 4  h, 
resulting in a linear pH gradient. The bed was divided into 15 fractions that were individually 
eluted with water.  The eluates were lyophilized, each was refiltered on Sephadex G-25, and 
the MMS activity in fractions 24-26 was determined. 
sufficient stimulus: (a) nonphagocytosable particles, such as C3b-coated Sepha- 
rose beads,  are effective; (b) latex beads,  while actively phagocytosed, do not 
cause MMS release; and (c) cytochalasin B-treated PM release MMS after zymosan 
exposure but do not internalize the zymosan. Thus, surface activation appears 
to be a sufficient stimulus for MMS release. 
The opsonic factor operant in serum-treated zymosan activation of PM appears 
to  be  dependent  on  C3  activation.  Again,  several  observations  support  this 
suggestion:  (a)  heat-inactivated  sera  failed  to  opsonize  the  zymosan;  (b)  C3- 
deficient sera were ineffective; (c) CVF-treated rat sera were ineffective; and (d) 
serum-treated Sepharose, which binds C3b to its surface (17),  was as active as 
serum-treated zymosan. 
Thus,  cell  surface  activation  of  PM  by  complement-derived opsonins  or 
through  Fc receptors (as  suggested by the protein  A  experiments) initiates a 
process that results in the release of a mucus secretagogue over a 4-8-h period. 
The time course of release suggested the possibility that synthesis or activation 
of this molecule is necessary before its release. 
The capacity of cycloheximide, which inhibits protein synthesis by reducing 
peptide bond formation (20), to affect MMS release was examined. Preincubating 
PM with cycloheximide prevented PM that were exposed to either S.  aureus or 
opsonized  zymosan  from  releasing  MMS.  These  cycloheximide-treated cells 
remained viable, as indicated by trypan blue dye exclusion, and phagocytically 
active, as reflected in apparent uptake of particles observed by phase microscopy. 
To  determine  if cycloheximide might  have  impaired  macrophage export  of 858  MACROPHAGE-DERIVED MUCUS  SECRETAGOGUE 
MMS, cell lysates were also examined and found largely devoid of MMS activity. 
The capacity of cycloheximide to inhibit new protein synthesis was monitored in 
parallel by following [3H]leucine incorporation into precipitable proteins; cyclo- 
heximide  inhibited  >90%  of new  protein  synthesis.  Thus,  MMS  is  a  newly 
synthesized molecule whose formation involves a cycloheximide-sensitive step. 
PM contain large amounts of esterified arachidonic acid in membrane phos- 
pholipids (21) and are prolific sources of many eicosinoids, including PG, throm- 
boxanes,  HETE,  and LT (22-25).  Human PM primarily produce LTB4 after 
stimulation with the calcium ionophore A-23187 (25). 
Earlier work using human airways demonstrated that arachidonic acid and 
many of its  oxidative  derivatives  possess  MMS  activity.  These  secretagogues 
include PGE1, PGF2~, PGD2, PGI2, and other PG (6); 5-, 8-, 9-,  11-,  12-, and 15- 
HETE, 5- and 9-hydroperoxyeicosatetraenoic acid (HPETE) (9); and LTC4 and 
LTD4  (7).  It  was  therefore  critically  important  to  examine  the  relationship 
between MMS and arachidonic acid. The first approach was to modulate cycloox- 
ygenase and  lipoxygenase enzymes by pharmacologic inhibitors.  Two  nonste- 
roidal antiinflammatory drugs, aspirin and indomethacin, did not influence MMS 
release  and  nor  did  ETYA.  Thus,  impairment  of either  or  both  enzymatic 
pathways involved in  the oxidation of arachidonic acid failed to influence PM 
MMS release. 
While these data mitigate strongly against MMS being a derivative of arachi- 
donic acid,  two additional experimental approaches were tried.  MMS was ex- 
tracted on three separate occasions with ethyl acetate or diethylether, and MMS 
failed to enter the organic phase of either solvent.  Moreover, MMS  failed to 
adhere to Amberlite XAD-7 resin in experiments in which LTB4 and LTC4 did 
adhere. Thus,  MMS  is not synthesized by cyclooxygenase or iipoxygenase en- 
zymes, is not extractable into organic solvents, and does not adhere to lipophilic 
resin. Therefore, it is very unlikely that MMS is an eicosinoid. 
Thereafter, MMS was characterized as to size and charge by ultramembrane 
filtration, gel filtration, and horizontal isoelectric focusing. MMS filtered through 
YM 10 membranes was retained by UM05 membranes, and filtered on Sephadex 
G-25 with an apparent molecular weight of 2,000.10 separate preparations were 
sized on  Sephadex  G-25  with  consistent results.  Isoelectric focusing of MMS 
revealed an acidic molecule (pI, 5.15).  Preparations of MMS after these purifi- 
cation steps displayed dose-related secretagogue activity, indicating that MMS is 
relatively stable. Thus, MMS is a small, acidic molecule, probably an oligopeptide. 
To our knowledge, the generation of similar molecules by macrophages have 
never previously been described. 
Summary 
Human pulmonary macrophages (PM) obtained from surgically removed hu- 
man lung tissue released a factor after exposure to activated zymosan that caused 
cultured human airways to release increased amounts of radiolabeled mucous 
glycoproteins. The factor was released maximally after 4-8 h of zymosan expo- 
sure and caused a  dose-related increase in glycoprotein release; it was termed 
macrophage-derived mucus secretagogue (MMS). MMS release was produced in 
a  dose-dependent fashion by activated but not by nonactivated zymosan. The MAROM,  SHELHAMER,  AND  KALINER  859 
activation of zymosan was C3 dependent, and C3b-coated Sepharose was also an 
effective stimulant. The data suggested that cell surface activation of the PM was 
a sufficient stimulus to cause MMS release and that both C3-dependent activation 
as  well  as  Fc  receptor  activation  were  effective.  The  synthesis  of MMS  was 
sensitive to cycloheximide, and no active MMS was detectable intracellularly. To 
determine if MMS might be one of the oxidative derivatives of arachidonic acid, 
PM  were  incubated  with  cyclooxygenase and  lipoxygenase  inhibitors  before 
activation.  These  manuevers  did  not  influence  MMS  generation.  MMS-rich 
supernatants  were then extracted into organic solvents or exposed to lipophilic 
resin; in both cases,  MMS remained in the aqueous phase. Thus, MMS is not a 
derivative of arachidonic acid.  Sequential fractionation of MMS  on ultramem- 
brane and gel filtration followed by isoelectric focusing and gel filtration indi- 
cated that MMS is a small (~2000 daltons), acidic (pI, 5.15) molecule. Therefore, 
surface activation  of human  PM  results in the synthesis and release of a  small 
acidic molecule that causes airway mucous glands to secrete increased quantities 
of mucous glycoproteins. 
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